CD11b+单核细胞比例与抗VEGF注射次数的关联
这项观察性队列研究纳入81例新生血管性AMD或PCV患者,发现基线CD11b+循环单核细胞比例可正向估计未来12、24、36个月抗VEGF注射次数。回顾性分析在更大样本中亦显示类似关联,提示该关联反映新生血管中的VEGF活性。
要点
- 基线CD11b+单核细胞比例与未来12、24、36个月抗VEGF注射次数正相关。
- 该关联在新生血管性AMD和PCV中均存在,提示反映VEGF活性。
- CD11b+单核细胞高表达CCR2,后者是促血管生成的重要单核细胞标志物。
核心结论
- 循环CD11b+单核细胞比例可估计并与新生血管性AMD和PCV患者的抗VEGF注射次数相关。
研究设计与样本
- 观察性队列研究,收集2010年至2013年及2015年至2018年数据,从丹麦单中心连续招募81例无免疫疾病患者。
- 患者因新生血管性AMD或PCV接受阿柏西普或雷珠单抗按需治疗36个月,采集新鲜静脉血行流式细胞免疫研究。
主要发现
- 基线CD11b+单核细胞比例正向估计未来抗VEGF注射次数:12个月ρ=0.77(95%CI 0.35-0.93;P=.004),24个月ρ=0.82(95%CI 0.44-0.95;P=.002),36个月ρ=0.78(95%CI 0.34-0.94;P=.005)。
- 回顾性分析更大样本的新生血管性AMD患者:12个月ρ=0.46(95%CI 0.16-0.68;P=.004),24个月ρ=0.49(95%CI 0.20-0.70;P=.002),36个月ρ=0.65(95%CI 0.41-0.80;P<.001)。
- PCV患者:12个月ρ=0.27(95%CI -0.28至0.68;P=.30),24个月ρ=0.60(95%CI 0.12-0.85;P=.02),36个月ρ=0.70(95%CI 0.27-0.90;P=.005)。
- CD11b+单核细胞高共表达CCR2,后者是促血管生成活性的重要单核细胞标志物。
临床怎么用
- CD11b+单核细胞比例或可作为估计抗VEGF治疗需求的潜在生物标志物,但尚需进一步研究验证其临床相关性。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: CD11b+ immune cells have been implicated in the formation of choroidal neovascularization in experimental studies on animals and disease-association studies on humans. However, the clinical importance of such observations remains unknown. OBJECTIVE: To investigate whether the proportion of CD11b+ circulating monocytes is associated with the number of anti-vascular endothelial growth factor (anti-VEGF) injections in neovascular age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV). DESIGN, SETTING, AND PARTICIPANTS: These observational cohort studies collected data from January 1, 2010, through December 31, 2013, and from January 1, 2015, through December 31, 2018. Fresh venous blood samples were acquired for flow cytometric immune studies in patients with neovascular AMD or PCV receiving treatment with aflibercept or ranibizumab as needed for 36 months. Patients (n = 81) without immune diseases were consecutively recruited from a single center in Denmark. EXPOSURES: Proportion of CD11b+ circulating monocytes. MAIN OUTCOMES AND MEASURES: The estimation of the number of intravitreal anti-VEGF injections given at 12, 24, and 36 months by the proportion of CD11b+ circulating monocytes and the correlation between these values. The angiogenic role of CD11b+ circulating monocytes was further evaluated by investigating the expression of the known proangiogenic receptor CCR2. RESULTS: Eighty-one patients were included in the analysis (54% women; mean [SD] age, 76 [7] years). The proportion of CD11b+ monocytes at baseline positively estimated the future number of anti-VEGF injections at 12 (ρ = 0.77; 95% CI, 0.35-0.93; P = .004), 24 (ρ = 0.82; 95% CI, 0.44-0.95; P = .002), and 36 (ρ = 0.78; 95% CI, 0.34-0.94; P = .005) months. This association was also found retrospectively in a larger sample of patients with neovascular AMD at 12 (ρ = 0.46; 95% CI, 0.16-0.68; P = .004), 24 (ρ = 0.49; 95% CI, 0.20-0.70; P = .002), and 36 (ρ = 0.65; 95% CI, 0.41-0.80; P < .001) months and patients with PCV at 12 (ρ = 0.27; 95% CI, -0.28 to 0.68; P = .30), 24 (ρ = 0.60; 95% CI, 0.12-0.85; P = .02), and 36 (ρ = 0.70; 95% CI, 0.27-0.90; P = .005) months, suggesting that this association is not specific to AMD but rather reflects VEGF activity in neovascularization. CD11b+ monocytes highly coexpressed CCR2, an important monocytic marker of proangiogenic activity. CONCLUSIONS AND RELEVANCE: Results of this study demonstrated that the proportion of circulating CD11b+ monocytes estimated and correlated with the number of anti-VEGF injections in patients with neovascular AMD and PCV. Additional longitudinal studies are needed to determine whether these findings have clinical relevance to influence treatment algorithms or provide novel targets for medical therapy.
引用
- Subhi Y, Krogh Nielsen M, Molbech CR, et al. Association of CD11b+ Monocytes and Anti-Vascular Endothelial Growth Factor Injections in Treatment of Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy. JAMA Ophthalmol. 2019. PMID: 30844038. doi:10.1001/jamaophthalmol.2019.0010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。